[ad_1]
Merck has struck a deal worth up to $1.3 billion to buy an investigational drug targeting B-cell associated diseases.
[ad_1]
Merck has struck a deal worth up to $1.3 billion to buy an investigational drug targeting B-cell associated diseases.
Atos is in talks with bondholders and banks after a consortium that included shareholder Onepoint…
CEO Glenn Chamandy is focusing on ways to both optimize production by using underused capacity…
Sales for Microsoft’s main cloud business fell just short of expectations last quarter, causing the…
Sign in to your account